Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ: RXRX · Real-Time Price · USD

3.310

+0.020 (0.61%)

At close: Aug 13, 2026, 4:00 PM EDT

3.300

-0.010 (-0.30%)

After-hours: Aug 13, 2026, 7:54 PM EDT

Recursion Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	545.68	743.29	594.35	391.57	549.91	285.12
Short-Term Investments	-	-	-	-	-	231.45
Cash & Short-Term Investments	545.68	743.29	594.35	391.57	549.91	516.56
Cash Growth	3.92%	25.06%	51.79%	-28.79%	6.46%	97.07%
Accounts Receivable	-	-	-	-	-	0.03
Other Receivables	14.39	24.65	49.17	3.09	2.75	9.06
Total Trade Receivables	14.39	24.65	49.17	3.09	2.75	9.09
Other Current Assets	43.39	44.9	70.75	43.48	17.15	9.07
Total Current Assets	603.46	812.85	714.27	438.14	569.81	534.72
Net Property, Plant & Equipment	147.07	169.48	233.21	120.17	121.45	64.73
Other Intangible Assets	282.89	309.9	335.86	36.44	1.31	1.39
Goodwill	160.35	162.16	148.87	52.06	0.8	0.8
Other Long-Term Assets	18.9	19.74	16.39	6.89	7.92	8.72
Total Assets	1,213	1,474	1,449	653.7	701.29	610.35

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	12.67	18.12	21.61	3.95	4.59	2.82
Accrued Expenses	56.94	70.23	81.87	46.64	32.9	32.33
Short-Term Debt	9.44	9.09	8.43	0.04	0.1	0.09
Current Portion of Leases	13.25	12.66	13.8	6.12	5.95	-
Unearned Revenue	27.59	37.61	61.77	36.43	56.73	10
Other Current Liabilities	-	-	-	-	-	1.42
Total Current Liabilities	119.89	147.71	187.47	93.17	100.27	46.66
Long-Term Debt	4.75	9.56	19.02	1.1	0.54	0.63
Long-Term Leases	39.19	46.65	67.25	43.41	44.42	-
Other Long-Term Liabilities	133.83	139.35	140.07	52.58	70.26	20.12
Total Long-Term Liabilities	177.78	195.56	226.34	97.09	115.22	20.75
Total Liabilities	297.67	343.27	413.82	190.26	215.48	67.41

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.01	0.01	0	0	0	0
Additional Paid-in Capital	3,212	3,170	2,474	1,431	1,125	943.14
Accumulated Other Comprehensive Income	27.99	36.72	-7.64	-	-	-0.13
Retained Earnings	-2,325	-2,076	-1,431	-967.62	-639.56	-400.08
Total Common Shareholders' Equity	915	1,131	1,035	463.44	485.81	542.94
Shareholders' Equity	915	1,131	1,035	463.44	485.81	542.94
Total Liabilities & Equity	1,213	1,474	1,449	653.7	701.29	610.35

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	66.64	77.97	108.49	50.67	51.01	0.72
Net Cash (Debt)	479.05	665.33	485.86	340.89	498.91	515.84
Net Cash Growth	9.61%	36.94%	42.52%	-31.67%	-3.28%	106.63%
Net Cash Per Share	0.94	1.49	1.77	1.64	2.84	4.12
Book Value	915	1,131	1,035	463.44	485.81	542.94
Book Value Per Share	1.80	2.53	3.77	2.23	2.77	4.33
Tangible Book Value	471.77	658.8	550.05	374.94	483.7	540.75
Tangible Book Value Per Share	0.93	1.47	2.01	1.80	2.76	4.31

SEC Filings: 10-K · 10-Q